Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual)

Trial Profile

Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary) ; Lamivudine (Primary) ; Abacavir/dolutegravir/lamivudine; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms Tridual
  • Most Recent Events

    • 01 Aug 2022 Results assessing immunological and inflammatory changes in virologically suppressed HIV-infected patients through week 96 published in the Clinical Microbiology and Infection
    • 27 Aug 2021 Status changed from active, no longer recruiting to completed.
    • 14 Aug 2020 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top